Back to Discover
Clinical GuidelineValid exact source

Preventing and responding to chemo extravasation at the bedside

Original source title: ONS Guidance: Safe Handling and Vesicant Extravasation Management

Oncology Nursing SocietyMar 15, 2026public source

Brief summary

ONS guidance reinforces safe chemotherapy administration and vesicant extravasation management: confirm access, monitor the site, recognize extravasation early, and follow the agent-specific response. Oncology nurses prevent and catch these events at the bedside.

What NurseJet pulled from the source

ONS guidance on chemotherapy and biotherapy administration reinforces the safe-handling and vesicant-management practices that protect both patients and nurses. Vesicants can cause severe tissue injury if they leak into surrounding tissue, so prevention, early recognition, and a prepared response are emphasized.

The guidance covers verifying a patent vascular access device, monitoring the site during administration, recognizing extravasation early (burning, swelling, loss of blood return, or resistance), and following a defined response: stop the infusion, aspirate, and apply the antidote or thermal measure appropriate to the agent.

For oncology nurses, the message is preparation plus vigilance: know which agents are vesicants, watch the site continuously, and have your extravasation kit and protocol ready before you start. Early recognition limits tissue damage and is squarely a bedside nursing responsibility.

Why this matters for nurses

Extravasation can cause lasting tissue damage, but most harm is preventable with vigilant monitoring and a fast, correct response. Oncology nurses control the access checks, site monitoring, and immediate response that determine the outcome.

Key takeaways

  • Vesicants can cause severe tissue injury if they extravasate — prevention and early recognition are key.
  • Verify a patent access device and monitor the site throughout administration.
  • Early signs: burning, swelling, loss of blood return, or resistance to infusion.
  • Response: stop, aspirate, and apply the agent-specific antidote/thermal measure per protocol.

Practice implications

  • Confirm blood return and line patency before and during vesicant administration.
  • Keep the extravasation kit and agent-specific protocol accessible before starting.
  • Educate patients to report any burning, stinging, or swelling at the site immediately.

Nursing assessment

  • Vascular access patency, blood return, and site appearance throughout infusion.
  • Patient-reported burning, pain, or stinging at the site.
  • Knowledge of which ordered agents are vesicants versus irritants.

Patient safety

  • Loss of blood return or new site pain during a vesicant infusion is an emergency — stop immediately.
  • Antidotes and thermal measures are agent-specific; using the wrong one can worsen injury.

Patient & family education

  • Tell patients to report any burning, pain, or swelling at the IV site right away.
  • Explain why the nurse checks the site so frequently during treatment.

Limitations & cautions

  • Protocols are agent-specific and follow facility policy and the drug reference.
  • Demo content is illustrative — verify specifics against current ONS guidance.

Citations

Exact source links

Public citations are filtered to exact approved source pages. Homepage-only or invalid links stay in admin review and are not shown here.

Oncology Nursing Society — Chemotherapy/biotherapy safe-handling and extravasation resources.

Oncology Nursing Society

Open original source

https://www.ons.org/clinical-tools/pep/extravasation-management

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover